TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6366135
Drug: L-phenylalanine mustard
Normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine mustard and 5-fluorouracil (PF)
Study: 30713751
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose misoprostol + cervical Foley catheter (Group 2)
Study: 15361383
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg triamcinolone hexacetonide (0.25 ml)
Study: 15361383
Drug: Sterile 0.9%
Normalized name: Sodium Chloride;Vancomycin Hydrochloride;Water, Sterile 0.9%; 1 GM Intravenous Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 0.9% saline (0.25 ml)
Study: 9531231
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium (initial dose 5 mg/d, increased to 10 mg/d at 24 months)
Study: 8232430
Drug: accelerated-dose tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: accelerated-dose tissue plasminogen activator (t-PA) with intravenous heparin
Study: 8232430
Drug: streptokinase with
Approvals — FDA: no, EMA: no, PMDA: no
Description: streptokinase with subcutaneous heparin
Study: 8232430
Drug: streptokinase with
Approvals — FDA: no, EMA: no, PMDA: no
Description: streptokinase with intravenous heparin
Study: 8232430
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of both activators plus intravenous heparin
Study: 1860196
Drug: all treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: all treatment groups
Study: 30818931
Drug: Rapid-enhanced group
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-enhanced group (40 μg at 0, 1, 2, 3 months; 60 μg at 4, 5, 6 months)
Study: 30818931
Drug: Rapid group
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid group (40 μg at 0, 1, 2, 3 months; 20 μg at 4, 5, 6 months)
Study: 26769956
Drug: Horizontal bed
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Horizontal bed rest combined with daily moderate intensity exercise (HAMB)
Study: 24120953
Drug: Vaniprevir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 24 weeks (n=16)
Study: 24120953
Drug: Vaniprevir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaniprevir (600 mg twice daily) for 24 weeks with peginterferon and ribavirin for 48 weeks (n=14)
Study: 24120953
Drug: Vaniprevir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaniprevir (300 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Study: 24120953
Drug: Vaniprevir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Study: 22990394
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (encouraged to increase daily steps to 10,000)
Study: 22990394
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not asked to change daily steps)
Study: 11524308
Drug: Acamprosate (1665‐1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1665‐1998 mg/day)
Study: 3284133
Drug: Heparin/Dihydroergotamine (HDHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/Dihydroergotamine (HDHE)
Study: 3284133
Drug: Heparin/Acenocoumarin (Hep/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/Acenocoumarin (Hep/S)
Study: 29347996
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylphenidate per day (4 over-encapsulated tablets)
Study: 24344672
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antibiotic impregnated cement (1 gram Clindamycin and 1 gram Gentamicin)
Study: 19090407
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection (5 microg in 0.2 mL)
Study: 19090407
Drug: Buffered isotonic
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered isotonic saline (control, 0.2 mL)
Study: 9387731
Drug: Tangshenkang (TSK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangshenkang (TSK) capsule
Study: 1415946
Drug: Oral examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral examination performance (grouped as honors, high satisfactory, satisfactory, unsatisfactory)
Study: 1415946
Drug: Oral examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral examination groups throughout the rotations
Study: 2991478
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus methanol extractable residue of BCG (MER-BCG)
Study: 30010061
Drug: Colistin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin monotherapy (loading dose of 9 MIU followed by 3 MIU every 8 hours)
Study: 30010061
Drug: Colistin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin + meropenem combination therapy (colistin 8.58 MIU and meropenem 1 g every 8 hours for 15 days)
Study: 21357882
Drug: Internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioural therapy (CBT)
Study: 23829297
Drug: Multispecies probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotics (Bifidobacterium longum, B. bifidum, B. lactis, Lactobacillus acidophilus, L. rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks
Study: 21775910
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 4 weeks
Study: 9656503
Drug: Lamaze preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamaze preparation
Study: 7625503
Drug: Spermicidal suppositories
Normalized name: lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermicidal suppositories
Study: 7625503
Drug: Foaming tablets
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foaming tablets
Study: 2464094
Drug: Dilevalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (400 mg)
Study: 321184
Drug: oxpentifylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxpentifylline (200 mg 3-times a day)
Study: 30852939
Drug: MEDI7510 (adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI7510 (adjuvanted RSV sF vaccine)
Study: 27567020
Drug: Orbital Atherectomy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital Atherectomy System (OAS) treatment in patients with eGFR < 90 ml/min/1.73 m2
Study: 27567020
Drug: Orbital Atherectomy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital Atherectomy System (OAS) treatment in patients with eGFR ≥ 90 ml/min/1.73 m2
Study: 23547848
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg (s.c.)
Study: 23547848
Drug: Tocilizumab 81
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 81 mg (s.c.)
Study: 21736720
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care program (watchful waiting, guided self‐help, short face‐to‐face problem solving treatment, pharmacotherapy and/or specialized mental health care)
Study: 10986540
Drug: ACE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE chemotherapy plus G‐CSF (granulocyte colony‐stimulating factor) at 2‐week intervals
Study: 10986540
Drug: ACE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE chemotherapy alone at standard 3‐week intervals
Study: 9076616
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg) three times daily for 4 weeks
Study: 9076616
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 4 weeks
Study: 8401051
Drug: Trimethylamine oral
Normalized name: trimethylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethylamine oral challenge (600 mg)
Study: 3045026
Drug: Defibrotide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (200 mg/day, intramuscular)
Study: 28377492
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (LDCT) screening for lung cancer, annual invitation for 4 years
Study: 28377492
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (LDCT) screening for lung cancer
Study: 23715925
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g intravenously 15-45 min before skin incision
Study: 11050580
Drug: Isotretinoin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (1 mg/kg) + Vitamin E (800 IU/day)
Study: 11050580
Drug: Isotretinoin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (1 mg/kg) + Vitamin E placebo
Study: 8265524
Drug: Erythromycin with
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin with midazolam 5 mg
Study: 8265524
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg with erythromycin
Study: 8265524
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg with roxithromycin
Study: 2872056
Drug: diacetolol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacetolol 600 mg
Study: 2879477
Drug: acebutolol 400
Normalized name: acebutolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol 400 mg
Study: 2872056
Drug: metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 200 mg
Study: 1687425
Drug: propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 80 mg
Study: 25397825
Drug: Acupuncture (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (8 sessions of 60 minutes each, twice weekly)
Study: 22915053
Drug: Temozolomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (200 mg/m² on days 1-5) and Bevacizumab (10 mg/kg on days 1 and 15) every 28 days (Regimen TB)
Study: 22915053
Drug: Nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (100 mg/m² or 80 mg/m² post-addendum on days 1, 8, and 15), Bevacizumab (10 mg/kg on days 1 and 15), and Carboplatin (AUC 6 on day 1 or AUC 5 post-addendum) every 28 days (Regimen ABC)
Study: 20860546
Drug: ABX‐IL8 (fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX‐IL8 (fully human IgG₂ monoclonal antibody)
Study: 16647911
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal gel (0.75%)
Study: 2339625
Drug: 1,25‐(OH)2D3 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25‐(OH)2D3 2 micrograms/day for 2 weeks before 3 months of sodium fluoride treatment 25 mg twice a day, in each 5‐month cycle
Study: 2339625
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) 25 mg twice a day with 1,25‐(OH)2D3 0.5 micrograms/day for 12 months in each 13‐month cycle
Study: 2339625
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including sodium fluoride treatment)
Study: 2339625
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride treatment
Study: 6109465
Drug: Flunitrazepam (0.4‐0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.4‐0.8 mg)
Study: 6109465
Drug: Benzoctamine (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoctamine (10‐20 mg)
Study: 16218045
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 60 mg/die
Study: 9740203
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of zinc (1200 microg/kg, ratio 4:1)
Study: 9740203
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of zinc (300 microg/kg, ratio 1:1)
Study: 8037087
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate (ISDN) infusion at 10 to 60 micrograms/min for 1 hour, 2 days, or 5 days
Study: 8037087
Drug: Intracoronary isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary isosorbide dinitrate (ISDN) bolus (1 mg)
Study: 28969715
Drug: Annual treatment
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual treatment with IVM + ALB
Study: 28969715
Drug: Biannual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual treatment with IVM + ALB (annual MDA followed by an additional MDA 6 months later)
Study: 24029871
Drug: Regular sodium
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular sodium diet (194±49 mmol Na/day) with lisinopril (40 mg/day)
Study: 24029871
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (102±52 mmol Na/day) with lisinopril (40 mg/day)
Study: 24029871
Drug: Regular sodium
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular sodium diet (194±49 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Study: 24029871
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (102±52 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Study: 15187504
Drug: AVP/NE infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP/NE infusion (4 units/hr)
Study: 15187504
Drug: NE infusion
Normalized name: Ne
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NE infusion only
Study: 15187504
Drug: AVP/NE infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP/NE infusion
Study: 9065344
Drug: Triprolidine hydrochloride
Normalized name: Triprolidine Hydrochloride
DrugBank: Triprolidine (DB00427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triprolidine hydrochloride 5 mg
Study: 8091379
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dermatan sulfate (MF701) b.i.d.
Study: 8091379
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dermatan sulfate (MF701) b.i.d.
Study: 8091379
Drug: Both dosages
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosages of dermatan sulfate (100 mg and 300 mg)
Study: 2517718
Drug: Prazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin therapy for one week
Study: 2517718
Drug: Prazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin therapy during hyperosmolar mannitol load
Study: 2517718
Drug: Prazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin therapy
Study: 1097597
Drug: Electrosleep treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrosleep treatment (24 live treatments)
Study: 30711664
Drug: Active online
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active online cognitive behavioral therapy (iCBT) intervention with EFI
Study: 30711664
Drug: Active online
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active online cognitive behavioral therapy (iCBT) intervention without EFI
Study: 26495881
Drug: Modified Dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Dual Therapy (MDT) with amoxicillin 750 mg thrice daily plus rabeprazole 20 mg thrice daily
Study: 26495881
Drug: Standard Quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Quadruple Therapy (SQT) with rabeprazole 20 mg b.i.d., bismuth subcitrate 120 mg q.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d.
Study: 26495881
Drug: Standard Quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Quadruple Therapy (SQT)
Study: 22950390
Drug: Phenylephrine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine at a dose of 0.3-0.4 μg.kg(‐1).min(‐1)
Study: 22950390
Drug: Dopamine and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine and/or dobutamine at 2-8 μg.kg(‐1).min(‐1)
Study: 16188156
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - 80 mg in one dose
Study: 16188156
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B - repeated epirubicin 40 mg q wk x 4-8 sessions followed by q month to the end of the second year
Study: 16188156
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C - 50 mg q month to the same duration
Study: 2704341
Drug: Recent aggressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent aggressive treatment protocols for ALL
Study: 2704341
Drug: Three-drug reinduction
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug reinduction program after consolidation
Study: 408433
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b polysaccharide vaccine
Study: 408433
Drug: N. meningitidis
Normalized name: N. MENINGITIDIS VACC (TRUMENBA) SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. meningitidis polysaccharide vaccine
Study: 30653086
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg elemental selenium daily)
Study: 27922453
Drug: Fostemsavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (400 mg twice daily)
Study: 27922453
Drug: Fostemsavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (800 mg twice daily)
Study: 27922453
Drug: Fostemsavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (600 mg once daily)
Study: 27922453
Drug: Fostemsavir (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (1,200 mg once daily)
Study: 27922453
Drug: Fostemsavir (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (various doses)
Study: 27922453
Drug: ATV/r (ritonavir-boosted
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r (ritonavir-boosted atazanavir 300/100 mg once daily)
Study: 24571193
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg methylnaltrexone
Study: 21646646
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily for 6 months
Study: 19888785
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (valsartan/HCTZ)
Study: 16920896
Drug: Tesaglitazar 1
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar 1 mg during fasting
Study: 16920896
Drug: Tesaglitazar 1
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar 1 mg after a high-fat, high-calorie breakfast
Study: 9261306
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with aqueous humor suppressants (n = 11)
Study: 9261306
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n = 11)
Study: 24173028
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine (single oral dose of ∼4.4 × 10(8) CFU)
Study: 19459475
Drug: Grifor vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grifor vaccine
Study: 7597114
Drug: Alprazolam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1.0 mg
Study: 19052126
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg once daily for 48 weeks
Study: 10947322
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 micrograms twice daily) via Pulvinal inhaler
Study: 10947322
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 micrograms twice daily) via Diskhaler inhaler
Study: 8874327
Drug: 5‐FU 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion (Group A)
Study: 8874327
Drug: 5‐FU 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion plus IFN 2b 5 million units subcutaneously three times weekly (Group B)
Study: 30071993
Drug: Ranolazine 1,000
Normalized name: Ranolazine 1,000mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 1,000 mg twice a day
Study: 28777224
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intracameral bevacizumab
Study: 25493621
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution as placebo